Irritable Bowel Syndrome (IBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Irritable bowel syndrome (IBS) is a prevalent medical condition characterized by chronic, recurrent abdominal pain, discomfort, and altered bowel habits. This condition occurs in the absence of other organic gastrointestinal (GI) diseases, and its underlying cause is still under investigation but is believed to involve multiple factors. The factors that may trigger disruptions in GI motor and sensory function include irritation from digestive byproducts, past gastroenteritis, internal irritants, gut microbiome changes, mucosal immune responses, food intolerance, and increased mucosal permeability. These underlying disruptions give rise to symptoms such as discomfort, gut motility changes, and bowel habit alterations. Genetic factors may also contribute to the development of IBS. BS can manifest with a wide array of gastrointestinal symptoms. While abdominal pain is one of the most common complaints, individuals with IBS may also experience bloating, a feeling of incomplete bowel emptying, urgency, diarrhea, straining, and constipation. The abdominal pain in IBS is typically crampy and varies in location and intensity. This pain is often associated with bowel movements, with some patients experiencing relief after bowel movements and others having worsening pain during them. Additionally, meals and emotional stress can exacerbate abdominal pain in some patients. Functional bowel disease experts established the Rome criteria to manage patients with abdominal symptoms resembling IBS. According to this classification, IBS is categorized based on the predominant stool pattern as follows:

·       IBS with predominant constipation (IBS-C): characterized by more than 25% hard stools and less than 25% loose stools.

·       IBS with predominant diarrhea (IBS-D): marked by more than 25% loose stools and less than 25% hard stools.

·       IBS with mixed bowel habits (IBS-M): characterized by more than 25% loose stools and more than 25% hard stools.

·       IBS unclassified (IBS-U): characterized by less than 25% loose stools and less than 25% hard stools.

·       The differential diagnosis for IBS is extensive. A comprehensive patient history, physical examination, and a few laboratory tests can help rule out conditions such as celiac disease, inflammatory bowel disease, microscopic colitis, post-cholecystectomy bile acid diarrhea, and small intestinal bacterial overgrowth (SIBO). Patients with IBS-C may also have pelvic floor dysfunction or colonic transit disorders. If treatment fails to alleviate symptoms, further evaluation may be necessary, including a rectal examination to identify patients with dyssynergia or pelvic floor issues. Management of IBS encompasses dietary adjustments, medication options, and mind-body treatments. The United States Food and Drug Administration (FDA) has approved two agents, lubiprostone and linaclotide, specifically for IBS-C treatment.

·       In the United States, IBS has a prevalence ranging from 7% to 16%, with a higher incidence in women and younger individuals.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Irritable Bowel Syndrome (IBS) – market outlook, epidemiology, competitive landscape, and market forecast report – 2022 to 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more